Live Breaking News & Updates on Autonomic Neuromodulation
Stay updated with breaking news from Autonomic neuromodulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023 ....
Published: Dec 18, 2020 Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota. Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system. NeuroClear intends to develop new intellectual properties and products, including new hardware, software, and algorithmic solutions, with the support of a tier 1 US-based manuf ....
BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota Westport, CT, Dec. 18, 2020 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota. Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system. NeuroClea ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of . BioSig Technologies, Inc.December 18, 2020 GMT Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota. Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address di ....